HEB Hemispherx BioPharma Inc.

0.34
+0.00  (0%)
Previous Close 0.34
Open 0.34
Price To book 0.97
Market Cap 9917562
Shares 29,169,300
Volume 164,771
Short Ratio 4.08
Av. Daily Volume 217,121

SEC filingsSee all SEC filings

  1. 8-K - Current report 171086137
  2. S-8 - Securities to be offered to employees in employee benefit plans 171064042
  3. 8-K - Current report 171055959
  4. 8-K - Current report 171046217
  5. 8-K - Current report 171032575

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL February 4, 2013.
Ampligen
CFS

Latest News

  1. ETFs with exposure to Hemispherx Biopharma, Inc. : September 9, 2017
  2. ETFs with exposure to Hemispherx Biopharma, Inc. : August 25, 2017
  3. Edited Transcript of HEB earnings conference call or presentation 15-Aug-17 5:00pm GMT
  4. Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
  5. Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended June 30, 2017
  6. Hemispherx Human Safety Study of Intranasal Ampligen® with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated
  7. Hemispherx Biopharma to Host Conference Call to Discuss Second Quarter Financial Results on Tuesday, August 15, 2017
  8. Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
  9. Hemispherx Encouraged by Cytokine Biomarker Discovery Which May Lead to a Diagnostic for Chronic Fatigue Syndrome
  10. Today's Research Reports on Stocks to Watch: Alnylam Pharmaceuticals and Hemispherx Biopharma
  11. ETFs with exposure to Hemispherx Biopharma, Inc. : July 10, 2017
  12. Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer
  13. ETFs with exposure to Hemispherx Biopharma, Inc. : June 28, 2017
  14. Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
  15. ETFs with exposure to Hemispherx Biopharma, Inc. : May 8, 2017
  16. Edited Transcript of HEB earnings conference call or presentation 7-Apr-17 3:00pm GMT

SEC Filings

  1. 8-K - Current report 171086137
  2. S-8 - Securities to be offered to employees in employee benefit plans 171064042
  3. 8-K - Current report 171055959
  4. 8-K - Current report 171046217
  5. 8-K - Current report 171032575
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 171031499
  7. DEF 14A - Other definitive proxy statements 17970209
  8. 8-K - Current report 17925647
  9. 424B3 - Prospectus [Rule 424(b)(3)] 17885712
  10. 8-K - Current report 17883400